Spinout News

Orchard Therapeutics highlights recent progress across HSC gene therapy portfolio and outlines key 2023 milestones

11 January 2023

Orchard Therapeutics logo

Orchard Therapeutics, a global gene therapy leader, has announced recent commercial and regulatory accomplishments and outlined key 2023 milestones, highlighting the strong potential of its hematopoietic stem cell (HSC) gene therapy platform to drive value for patients, providers and shareholders.

As a leader in the development, manufacturing and commercialisation of HSC gene therapies, Orchard is well-positioned to leverage its expertise to provide potentially curative treatments to people suffering from a broad range of severe diseases with a single administration. To date, over 170 patients have been treated with Orchard’s current and former HSC gene therapy programs across seven different diseases, reflecting the broad clinical applicability of the company’s approach.

“Looking ahead to the first half of 2023, we will maintain our disciplined strategy and stewardship of capital as we focus on execution and achieving our regulatory and clinical milestones while remaining open to partnership opportunities that could accelerate growth and value creation,” said Bobby Gaspar, M.D., Ph.D., chief executive officer.

Read the full story from Orchard.